We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-26.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$455M
AUM Growth
-$327M
Cap. Flow
-$168M
Cap. Flow %
-36.97%
Top 10 Hldgs %
79.01%
Holding
161
New
35
Increased
35
Reduced
40
Closed
40

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.02M
3
ESPR
Esperion Therapeutics
ESPR
+$1.86M
4
RSLS
ReShape Lifesciences Inc. Common Stock
RSLS
+$1.72M
5
LFWD icon
ReWalk Robotics
LFWD
+$1.65M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.71M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$5.7M
3
FOLD
Amicus Therapeutics
FOLD
+$1.87M
4
APTX
Aptinyx Inc. Common Stock
APTX
+$1.19M
5
VKTX icon
Viking Therapeutics
VKTX
+$1.09M

Sector Composition

Rank Sector Weight
1 Healthcare 21.24%
2 Technology 0.34%
3 Consumer Staples 0.21%
4 Financials 0.17%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATOS icon
51
Atossa Therapeutics
ATOS
$24.1M
$513K 0.11%
33,497
+2,494
+8% +$49.3K
HYPD
52
Hyperion DeFi Inc
HYPD
$36.7M
$505K 0.11%
2,214
+172
+8% +$48.5K
NURO
53
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$505K 0.11%
8,302
+3,641
+78% +$304K
ALT icon
54
Altimmune
ALT
$581M
$490K 0.11%
+237,921
New +$842K
PALI icon
55
Palisade Bio
PALI
$351M
$490K 0.11%
+17
New +$976K
HURA
56
TuHURA Biosciences
HURA
$136M
$488K 0.11%
+81
New +$786K
IPCI
57
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$469K 0.1%
+1,944,978
New +$1.2M
SCON
58
DELISTED
Superconductor Technologies Inc.
SCON
$421K 0.09%
32,629
+3,834
+13% +$64.7K
AYTU icon
59
AYTU BioPharma
AYTU
$22.9M
$408K 0.09%
2,575
+2,398
+1,355% +$528K
SCPX
60
DELISTED
Scorpius Holdings, Inc.
SCPX
$384K 0.08%
+14
New +$592K
ZSAN
61
DELISTED
Zosano Pharma Corporation
ZSAN
$355K 0.08%
4,783
-2,382
-33% -$302K
SNOA icon
62
Sonoma Pharmaceuticals
SNOA
$5.46M
$331K 0.07%
+2,583
New +$515K
OPGN
63
DELISTED
OpGen, Inc
OPGN
$326K 0.07%
63
+59
+1,475% +$314K
RKDA icon
64
Arcadia Biosciences
RKDA
$1.37M
$303K 0.07%
2,394
-4,542
-65% -$763K
JAGX icon
65
Jaguar Health
JAGX
$4.74M
– –
0
– –
CARM
66
PUT
DELISTED
Carisma Therapeutics
CARM
$260K 0.06%
92
+1
+1% +$32
MNKD icon
67
PUT
MannKind Corp
MNKD
$1.21B
$253K 0.06%
2,388
-4,766
-67% -$8.09K
GRCE
68
Grace Therapeutics
GRCE
$36.6M
$229K 0.05%
+5,729
New +$250K
SOLO
69
DELISTED
Electrameccanica Vehicles Corp. Ltd.
SOLO
$213K 0.05%
+200,000
New +$397K
AIXC
70
AIxCrypto Holdings Inc
AIXC
$16.7M
$206K 0.05%
27
+19
+238% +$273K
RSLS
71
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
$187K 0.04%
732,648
+729,350
+22,115% +$1.72M
BLIN icon
72
Bridgeline Digital
BLIN
$14.9M
$180K 0.04%
+15,580
New +$359K
NOVN
73
DELISTED
Novan, Inc. Common Stock
NOVN
$177K 0.04%
21,306
-3,790
-15% -$77.4K
ISEE
74
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$173K 0.04%
1,438
+221
+18% +$428
ARMP icon
75
Armata Pharmaceuticals
ARMP
$174M
$168K 0.04%
+58,293
New +$284K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sabby Management held 161 positions worth $455M, down 42% from $782M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Sabby Management withdrew a net $168M in Q4 2018, closing 40 positions and reducing 40 holdings. Its most notable exit was Amicus Therapeutics, an estimated $1.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 15% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in State Street SPDR S&P Biotech ETF worth $4.47M.

  • Sabby Management's largest Q4 2018 buy was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.
  • Sabby Management added most to Biogen in Q4 2018, an estimated $28.9M increase.
  • Sabby Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $8.71M.
  • Sabby Management fully exited Amicus Therapeutics in Q4 2018, selling an estimated $1.87M.
  • Sabby Management's ten largest holdings make up 79% of its $455M portfolio in Q4 2018.
  • Sabby Management opened 35 new positions and closed 40 in Q4 2018.
  • Sabby Management's portfolio value fell 42% quarter-over-quarter to $455M.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.